Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

839.48
-3.9950-0.47%
Volume:41.73K
Turnover:34.89M
Market Cap:86.43B
PE:20.76
High:841.45
Open:840.06
Low:833.79
Close:843.47
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:4.92
T/O Rate:0.04%
Dividend:3.64
Dividend Rate:0.43%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.73
PE(LYR):20.24

Loading ...

Movement Alert|Regeneron Pharmaceuticals Rises 3.05% in Regular Trading, Biotech Sector Rallies Broadly Ahead of Q2 Earnings

Market Focus
·
Jul 28

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 28

Movement Alert|Regeneron Pharmaceuticals Rises 3.08% in Regular Trading, Trading at $676.44

Market Focus
·
Jul 27

Legend Biotech Names Alan Bash Interim CEO After Ying Huang Resigns

Reuters
·
Jul 27

Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN)

Simply Wall St.
·
Jul 27

The Scientist with 1,000 Patents Fueling a Drug Powerhouse

Dow Jones
·
Jul 25

Earning Preview: Regeneron Pharmaceuticals—this quarter’s revenue is expected to increase by 16.16%, and institutional views are predominantly bullish

Earnings Agent
·
Jul 24

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23

Movement Alert|Regeneron Pharmaceuticals Falls 3.28% in Regular Trading, Multiple Investment Banks Cut Target Prices Amid Earnings Warning

Market Focus
·
Jul 23

What Bundibugyo Ebola Vaccines and Treatments are Under Development

Reuters
·
Jul 22

Regeneron (REGN) Receives a Buy from Goldman Sachs

TIPRANKS
·
Jul 22

Analysts Are Bullish on These Healthcare Stocks: Valneva (VALN), Regeneron (REGN)

TIPRANKS
·
Jul 22

Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors

TIPRANKS
·
Jul 22

Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785

MT Newswires Live
·
Jul 22

Regeneron Pharma is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Telix Expects Fy2026 Revenue and Other Income Above US$1 Billion, Tracks Upper End of Guidance Range

Reuters
·
Jul 21

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Biohaven enters into clinical supply agreement with Regeneron

TIPRANKS
·
Jul 20

Biohaven Signs Regeneron Supply Deal to Test Bhv-1530 with Libtayo

Reuters
·
Jul 20

Merck Gets US FDA Nod for First-in-its-class Oral Cholesterol Drug

Reuters
·
Jul 16